Therapeutic efficacy in inflammatory diseases is hampered by disease complexity. A monoclonal antibody that neutralizes IL-1R3, the common co-receptor of most inflammatory IL-1 cytokines, opens up new perspectives in effective disease management.
ANTIBODY THERAPY One hits (almost) all
Boraschi Diana;
2019
Abstract
Therapeutic efficacy in inflammatory diseases is hampered by disease complexity. A monoclonal antibody that neutralizes IL-1R3, the common co-receptor of most inflammatory IL-1 cytokines, opens up new perspectives in effective disease management.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
